Fulltext

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

Keam B 1 , Machiels JP 2 , Kim HR 3 , Licitra L 4 , Golusinski W 5 , Gregoire V 6 Show all authors , Lee YG 7 , Belka C 8 , Guo Y 9 , Rajappa SJ 10 , Tahara M 11 , Azrif M 12 , Ang MK 13 , Yang MH 14 , Wang CH 15 , Ng QS 16 , Wan Zamaniah WI 17 , Kiyota N 18 , Babu S 19 , Yang K 20 , Curigliano G 21 , Peters S 22 , Kim TW 23 , Yoshino T 24 , Pentheroudakis G 25

Affiliations 

  • 1 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: bhumsuk@snu.ac.kr
  • 2 Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium
  • 3 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
  • 4 Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
  • 5 Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, Poland
  • 6 Department of Radiation Oncology, Centre Léon Bérard, Lyon, France
  • 7 Division of Hematology and Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • 8 Department of Radiation Oncology, LMU Hospital, Munich, Germany
  • 9 Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
  • 10 Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
  • 11 Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
  • 12 Clinical Oncology, Prince Court Medical Centre, Kuala Lumpur, Malaysia
  • 13 Department of Medical Oncology, National Cancer Centre, Singapore, Singapore
  • 14 Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
  • 15 Division of Hemato-oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan
  • 16 Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
  • 17 Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 18 Oncology/Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan
  • 19 Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
  • 20 Department of Clinical Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 21 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Istituto Europeo di Oncologia, IRCCS, Milano, Italy
  • 22 Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
  • 23 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 24 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center East, Chiba, Japan
  • 25 ESMO, Lugano, Switzerland
ESMO Open, 2021 Dec;6(6):100309.
PMID: 34844180 DOI: 10.1016/j.esmoop.2021.100309

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of squamous cell carcinoma (SCC) of the oral cavity, larynx, oropharynx and hypopharynx was published in 2020. It was therefore decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special, virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider the potential ethnic differences associated with the treatment of SCCs of the head and neck (SCCHN) in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with SCCHN (excluding nasopharyngeal carcinomas) representing the oncological societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter was discussed when appropriate. This manuscript provides a series of expert recommendations (Clinical Practice Guidelines) which can be used to provide guidance to health care providers and clinicians for the optimisation of the diagnosis, treatment and management of patients with SCC of the oral cavity, larynx, oropharynx and hypopharynx across Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications